Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03016598 · ClinicalTrials.gov registry record · Phase 2
Stimulant Oxytocin Study
A Phase 2 study of Stimulant Use & Co-occuring Opioid Use Disorders, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 3
- Study locations
NCT03016598: Completed Phase 2 study of Stimulant Use & Co-occuring Opioid Use Disorders, sponsored by VA Office of Research and Development.
NCT03016598 is a Phase 2 study of Stimulant Use & Co-occuring Opioid Use Disorders that has completed, run by VA Office of Research and Development. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03016598, a Phase 2 study of Stimulant Use & Co-occuring Opioid Use Disorders, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with stimulant use disorders and enrolled in opioid replacement therapy (ORT) program for co-occurring opioid use disorder (OUD).
Primary Outcome
Aim 1: To evaluate the effectiveness of intranasal oxytocin on reducing stimulant use.
Conditions Studied
Interventions
- DRUG Intranasal oxytocin
- DRUG Intranasal placebo
Study Locations (3)
California
- VA Northern California Health Care System, Mather, CA - Sacramento
- San Francisco VA Medical Center, San Francisco, CA - San Francisco
Oregon
- VA Portland Health Care System, Portland, OR - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2020-02-14 |
| Phase | Phase 2 |
What the finished NCT03016598 record still lists
NCT03016598 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Stimulant Use & Co-occuring Opioid Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Intranasal oxytocin is the first listed.
NCT03016598 reports a single indexed study location in California, Oregon.
Frequently Asked Questions
What is clinical trial NCT03016598 about?
NCT03016598 is a clinical study titled "Stimulant Oxytocin Study". This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with stimulant use disorders and enrolled in opioid replacement therapy (ORT)...
What is the current status of trial NCT03016598?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2018-01-26. Estimated completion is 2020-02-14.
What conditions does trial NCT03016598 study?
This clinical trial studies the following conditions: Stimulant Use & Co-occuring Opioid Use Disorders.
What interventions are being tested in trial NCT03016598?
The interventions under investigation include: Intranasal oxytocin (DRUG), Intranasal placebo (DRUG).
Who is sponsoring clinical trial NCT03016598?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03016598 being conducted?
This trial has 3 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03016598's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI